Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis

Journal of Occupational and Environmental Medicine

Volumn 51, Issue 10, 2009, Pages 1167-1176

  Birnbaum, Howard ^a   Pike, Crystal ^a   Kaufman, Rebecca ^a   Cifaldi, Mary ^b  

^a ANALYSIS GROUP   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR;

ABSENTEEISM; ARTICLE; CONTROLLED STUDY; DISABILITY; FEMALE; HEALTH CARE COST; HUMAN; JOB ADAPTATION; MALE; MEDICAL LEAVE; PRODUCTIVITY; RHEUMATOID ARTHRITIS; TURNOVER TIME; WORKPLACE;

EID: 70350179472     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181b8c397     Document Type: Article

References (35)

1. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med. 2000;42:588-596.
2. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum. 1995;38:1351-1362.
3. Yelin E. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates. J Rheumatol. 1996;23(Suppl): 47-51.
4. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: An international long-term view. Semin Arthritis Rheum. 2000;29:305-320.
5. Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M. Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature. Expert Opin Pharmacol. 2009;10:255-269.
6. Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med. 2006;48:135-148.
7. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol. 2005;32:583-589.
8. Verstappen SM, Boonen A, Bijlsma J, et al. Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions. Rheumatology. 2005;44:202-206.
9. Eberhardt K, Larsson BM, Nived K, Lindgvist E. Work disability in rheumatoid arthritis: development over 15 years and evaluation of predictive factors over time. J Rheumatol. 2007;34:481-487.
10. Fautrel B, Clarke AE, Guillemin F, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making. 2007;27: 138-150.
11. Lacaille D, Sheps S, Spinelli JJ, Chalmers A, Esdaile JM. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum. 2004;51:843-852.
12. Walker N, Michaud K, Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol. 2005;32:1006-1012.
13. Lerner D, Adler DA, Chang H, et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv. 2004;55: 1371-1378.
14. Mancuso CA, Paget SA, Charlson ME. Adaptations made by rheumatoid arthritis patients to continue working: A pilot study of workplace challenges and successful adaptations. Arthritis Care Res. 2000;13:89-99.
15. van den Hout WB, de Buck PD, Vliet Vlieland TP. Cost-utility analysis of a multidisciplinary job retention vocational rehabilitation program in patients with chronic arthritis at risk of job loss. Arthritis Rheum. 2007;57:778-786.
16. Kimel M, Cifaldi M, Chmiel J, Chen N, Revicki D. Norm-based interpretation of SF-36 improvements for adalimumab plus methotrexate (MTX) combination therapy versus MTX alone in early rheumatoid arthritis. Ann Rheum Dis. 2007;66(Suppl II):176-177 (Abstract THU0169).
17. van Vollenhoven RF, Farraccioli GF, Breedveld FC, Ray S, Cifaldi M. Effect of adalimumab combination therapy on work performance: results from a companion study to PREMIER. Arthritis Rheum. 2007;56(Suppl):S88. Poster Presentation 98 at the 2007 Annual Scientific Meeting of the American College of Rheumatology, November 6-11, 2007, Boston, MA.
18. Halpern M, Cifaldi M, Kvien T. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registrybased control group. Ann Rheum Dis. 2009;68:930-937.
19. Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM. Personal and economic burden of latestage rheumatoid arthritis among patients treated with adalimumab: An evaluation from a patient's perspective. Rheumatology. 2008;47:188-193.
20. Burton WN, Morrison A, Yuan Y, Li T, Marioni RE, Maclean R. Productivity cost model of the treatment of rheumatoid arthritis with abatacept. J Med Economics. 2008;11:3-21.
21. US Department of labor. Bureau of labor statistics. Available at: http://www.bls. gov/. Accessed February 20, 2009.
22. US Census Bureau. Money income in 2005. Available at: http://www.census. gov/population/www/pop-profile/files/ dynamic/MoneyIncome.pdf. Accessed February 20, 2009.
23. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang b, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum. 2008;59:1082-1089.
24. Zhang W, Bansback N, Guh D, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol. 2008;35:1729-1736.
25. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl):39-53.
26. Kavanaugh A, Han C, Bala M, Marsters P, Antoni C. Successful treatment improves employability in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(Suppl I):342 (Abstract SAT0327). Presented at the European League Against Rheumatism Annual Congress; Stockholm, Sweden; 2002.
27. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:3046-3054.
28. Geborek P, Eberhardt K, Larsson B, Nived K, Saxne T. Etanercept and infliximab treatment improves working capacity in arthritis patients. Ann Rheum Dis. 2002; 61(Suppl I):171 (Abstract FRI0038). Presented at the European League Against Rheumatism Annual Congress; Stockholm, Sweden; 2002.
29. Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis. 2006;65:924-928.
30. Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54:716-722.
31. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004;31: 849-855.
32. Allaire S, Wolfe F, Niu J, Lavalley M, Michaud K. Work disability and its economic economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum. 2005;53:603-608.
33. Birnbaum H. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics. 2005;23:103-104.
34. Bejarano O, Reece R, Quinn M, et al. Job loss in patients with early rheumatoid arthritis can be prevented by early use of the anti-tumor necrosis factor adalimumab: results of the PRevention Of Work Disability (PROWD) study. Arthritis Care Res. 2008;59:1467-1474.
35. US Department of Labor. Bureau of Labor Statistics. Economic news release: Employer costs for employee compensation summary. Available at: http:// www.bls.gov/news.release/ecec.nr0.htm. Accessed February 20, 2009.